Arch Biopartners Secures IRB Approval for Phase II LSALT Peptide Kidney Injury Trial

Arch Biopartners has received central Institutional Review Board approval to expand U.S. clinical sites for a Phase II trial evaluating LSALT Peptide in patients undergoing cardiac surgery.

31 Aug, 12:20 — 31 Aug, 12:20

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual4d ago

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide - Taiwan News

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide Taiwan News

Read full article →

Arch Biopartners Secures IRB Approval for Phase II LSALT Peptide Kidney Injury Trial

Sources

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide - Taiwan News

Related Stories

Haze Drives Unhealthy Air Quality Across Southeast Asian Cities

Experimental Heart Drug Fails Key Trial Milestone

6-week-old infant died of measles, Pennsylvania county coroner says - edition.cnn.com

Salmonella Outbreak Linked to Pumpkin Seeds Infects Over 80 in France